Agent skill
mpn-research-assistant
Install this agent skill to your Project
npx add-skill https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/mpn-research-assistant
SKILL.md
name: mpn-research-assistant description: "Myeloproliferative neoplasm (MPN) research expertise including JAK2/CALR/MPL mutations, myelofibrosis, polycythemia vera, essential thrombocythemia. Use for MPN literature search, driver mutation analysis, PPM1D pathway analysis, fibrosis markers, megakaryocyte biology, clinical trial data interpretation, and translational research." license: Proprietary
MPN Research Assistant
Disease Classification
WHO 2022 Classification
- Polycythemia Vera (PV): JAK2V617F (95%), JAK2 exon 12 (3%)
- Essential Thrombocythemia (ET): JAK2V617F (55%), CALR (25%), MPL (5%)
- Primary Myelofibrosis (PMF): JAK2V617F (55%), CALR (25%), MPL (8%)
- Pre-PMF: Early fibrotic stage, better prognosis
- Overt PMF: Grade 2-3 fibrosis, splenomegaly
Driver Mutations
| Mutation | Gene Location | Mechanism | VAF Significance |
|---|---|---|---|
| JAK2V617F | 9p24.1 | Constitutive JAK-STAT activation | >50% → poor prognosis |
| CALR (type 1) | 19p13.2 | 52bp deletion, MPL activation | Better prognosis |
| CALR (type 2) | 19p13.2 | 5bp insertion, MPL activation | Intermediate |
| MPL W515L/K | 1p34.2 | TPO-independent signaling | Thrombocytosis |
High Molecular Risk (HMR) Mutations
- ASXL1, EZH2, SRSF2, IDH1/2, U2AF1
- ≥2 HMR mutations = very high risk
PPM1D Pathway Analysis
Expression Patterns
- 83.9-fold overexpression vs normal donors (p=0.0002)
- JAK2V617F+ > CALR+ expression (43.4x vs 13.4x, p=0.01)
- Mutation frequency: 1.9% (8th most common in MPNs)
Therapeutic Targets
ppm1d_targets = {
'PPM1D inhibitors': ['GSK2830371', 'SL-176'],
'MDM2 inhibitors': ['navtemadlin (KRT-232)', 'idasanutlin'],
'Combination': ['PPM1D + MDM2 (synergistic)'],
}
# p53 pathway restoration
mechanism = """
PPM1D inhibition → ↑p53 phosphorylation →
↑p53 stabilization → ↑DNA damage response →
↑apoptosis in mutant clones
"""
Clinical Trial Data (BOREAS)
- Navtemadlin: 15% SVR35, 24% TSS50
- CD34+ reduction: 68-76% at 24-36 weeks
- VAF reduction: 21% achieved ≥50% decrease
- Fibrosis improvement: 45% by one grade
Megakaryocyte Subtypes in MPNs
mk_subtypes = {
'Endomitotic MKs': {
'markers': ['ITGA2B', 'GP1BA', 'PF4', 'TUBB1'],
'function': 'Polyploidization',
'mpn_change': 'Dysregulated endomitosis'
},
'Platelet-Generating MKs': {
'markers': ['VWF', 'F2R', 'GP9', 'SELP'],
'function': 'Proplatelet formation',
'mpn_change': 'Abnormal platelet production'
},
'HSC Niche-Supporting MKs': {
'markers': ['THPO', 'IGF1', 'CXCL12', 'ANGPT1'],
'function': 'HSC maintenance',
'mpn_change': 'Disrupted niche signaling'
},
'Inflammatory MKs': {
'markers': ['S100A8', 'S100A9', 'CHI3L1', 'CXCL8'],
'function': 'Inflammation',
'mpn_change': 'Expanded in MF'
}
}
Fibrosis Markers
Psaila 2020 Fibrosis Gene Signature
fibrosis_genes = [
'TGFB1', 'IL12A', 'IL1B', 'RAB37', 'TIMP1', 'APIP', 'PF4V1', 'VEGFA',
'FBLN2', 'SFRP1', 'COL6A2', 'COL4A2', 'COL5A1', 'PDGFRB', 'LOXL2', 'RUNX2'
]
# ECM remodeling
ecm_markers = ['COL1A1', 'COL3A1', 'FN1', 'LAMA1', 'LAMB1']
# Profibrotic cytokines
cytokines = ['TGFB1', 'PDGF', 'VEGFA', 'IL1B', 'IL6', 'TNF']
Prognostic Scoring Systems
MIPSS70+ v2.0 (Myelofibrosis)
| Variable | Points |
|---|---|
| Hemoglobin <10 g/dL | 2 |
| Blasts ≥2% | 1 |
| Constitutional symptoms | 2 |
| Absence of CALR type-1 | 2 |
| HMR mutations | 2 each |
| Unfavorable karyotype | 3 |
Risk Categories
- Very Low: 0-1 points (10yr OS: 92%)
- Low: 2-4 points
- Intermediate: 5-8 points
- High: 9-11 points
- Very High: ≥12 points
Data Integration Template
def create_mpn_patient_matrix(clinical_df, mutations_df,
cytokines_df, flow_df, degs_df):
"""Integrate multi-modal MPN patient data."""
# Merge clinical
matrix = clinical_df.copy()
# Add mutation status
driver_muts = ['JAK2', 'CALR', 'MPL']
hmr_muts = ['ASXL1', 'EZH2', 'SRSF2', 'IDH1', 'IDH2']
for mut in driver_muts + hmr_muts:
if mut in mutations_df.columns:
matrix[f'{mut}_status'] = mutations_df[mut]
# Calculate HMR count
matrix['HMR_count'] = matrix[[f'{m}_status' for m in hmr_muts
if f'{m}_status' in matrix.columns]].sum(axis=1)
# Add cytokine data
for cyto in ['TGFB1', 'IL6', 'IL8']:
if cyto in cytokines_df.columns:
matrix[f'{cyto}_level'] = cytokines_df[cyto]
# Add flow cytometry
matrix['CD34_percent'] = flow_df['CD34_positive_percent']
return matrix
Key References
key_papers = {
'Williams_2022': 'Blood: Phylogenetic reconstruction of MPN evolution',
'Psaila_2020': 'Nature Medicine: Single-cell profiling of MF megakaryocytes',
'Mascarenhas_2022': 'Blood Advances: Idasanutlin in PV',
'BOREAS_2024': 'Phase III navtemadlin in MF',
'Marcellino_iPSC': 'PPM1D iPSC modeling in MPNs',
'Kanagal-Shamanna': 'Mod Pathol: i(17q) in MDS/MPN'
}
PubMed Search Templates
mpn_search_queries = {
'ppm1d_mpn': '"PPM1D"[Title/Abstract] AND ("myeloproliferative"[Title/Abstract] OR "myelofibrosis"[Title/Abstract])',
'single_cell_mpn': '"single-cell"[Title/Abstract] AND "myeloproliferative neoplasm"[Title/Abstract]',
'jak2_calr': '(JAK2V617F OR "CALR mutation") AND myeloproliferative',
'fibrosis_mk': 'megakaryocyte[Title/Abstract] AND fibrosis[Title/Abstract] AND myelofibrosis'
}
See references/mpn_clinical_trials.md for ongoing trials.
See references/mpn_mutations_database.md for complete mutation catalog.
Recommended Agent Skills
Expand your agent's capabilities with these related and highly-rated skills.
vcf-annotator
Annotate VCF variants with VEP, ClinVar, gnomAD frequencies, and ancestry-aware context. Generates prioritised variant reports.
chemist-analyst
Analyzes events through chemistry lens using molecular structure, reaction mechanisms, thermodynamics, kinetics, and analytical techniques (spectroscopy, chromatography, mass spectrometry). Provides insights on chemical processes, material properties, reaction pathways, synthesis, and analytical methods. Use when: Chemical reactions, material analysis, synthesis planning, process optimization, environmental chemistry. Evaluates: Molecular structure, reaction mechanisms, yield, selectivity, safety, environmental impact.
bio-alignment-io
Read, write, and convert multiple sequence alignment files using Biopython Bio.AlignIO. Supports Clustal, PHYLIP, Stockholm, FASTA, Nexus, and other alignment formats for phylogenetics and conservation analysis. Use when reading, writing, or converting alignment file formats.
sleep-analyzer
分析睡眠数据、识别睡眠模式、评估睡眠质量,并提供个性化睡眠改善建议。支持与其他健康数据的关联分析。
metabolomics-workbench-database
Access NIH Metabolomics Workbench via REST API (4,200+ studies). Query metabolites, RefMet nomenclature, MS/NMR data, m/z searches, study metadata, for metabolomics and biomarker discovery.
bio-hi-c-analysis-matrix-operations
Balance, normalize, and transform Hi-C contact matrices using cooler and cooltools. Apply iterative correction (ICE), compute expected values, and generate observed/expected matrices. Use when normalizing or transforming Hi-C matrices.
Didn't find tool you were looking for?